Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

GLP-2 TIRZInterpret the evidence

Why the heart outcomes trial used an active comparator

3 numbered sourcesSource years 2022–2026

Peptides are short chains of amino acids joined by peptide bonds. Some are designed to engage more than one receptor. Tirzepatide activates GIP and GLP-1 receptors. The catalog wording “GLP-2 TIRZ” refers to tirzepatide and does not identify a GLP-2 target. The SURPASS-CVOT trial compared tirzepatide with dulaglutide to assess major cardiovascular events in adults with type 2 diabetes and atherosclerotic cardiovascular disease. [1, 2]

Dulaglutide is a GLP-1 receptor agonist with previous evidence on cardiovascular events. Comparing two active treatments addressed what happened when participants were assigned to tirzepatide or a drug already used in that setting. The researchers tracked a combined outcome of cardiovascular death, heart attack or stroke. More than 13,000 people underwent randomization. About 12.2% in the tirzepatide analysis group and 13.1% in the dulaglutide group experienced a primary outcome event. [1]

The trial was designed to test noninferiority. Before starting, the investigators set a statistical margin for how much worse tirzepatide could be and still meet their specified standard. The hazard ratio was 0.92, with a confidence interval from 0.83 to 1.01 under the trial’s calculation. The upper bound met the noninferiority margin. It crossed 1.00, and the trial did not establish statistical superiority on the primary outcome. The distinction helps explain why a lower event percentage alone does not settle whether one treatment outperformed the other. [1]

The 2026 U.S. Mounjaro label includes reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. That is a labeled indication for the particular product. The trial result describes a comparison with dulaglutide among adults who already had atherosclerotic cardiovascular disease. It does not estimate what would have happened with placebo in the same randomized population. [1, 3]

The study also recorded adverse events and reported more gastrointestinal events in the tirzepatide group. This is part of the head-to-head evidence, alongside the event counts and the uncertainty around the estimate. Reading the comparator, population and prespecified statistical question together provides a more accurate account than simply comparing the two percentages. [1]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop GLP-2 TIRZ

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.